Assessment of the Clinical and Medico-economic Impact of SinnoTest® in Patients With Rheumatoid Arthritis
Status:
Withdrawn
Trial end date:
2023-09-01
Target enrollment:
Participant gender:
Summary
Rheumatoid arthritis (RA) is one of the main chronic inflammatory rheumatic diseases (RCI),
with a prevalence of about 0.4% of the population.
First-line treatment with immunomodulators (synthetic and biological Disease Modifying
Anti-Rheumatic Drugs (sDMARDs) including methotrexate) is not sufficiently effective in 40%
of cases. These patients are then treated with biological Disease Modifying Anti-Rheumatic
Drugs (bDMARDs) called biotherapies. As the use of these bio-drugs increases each year, they
become a major public health and economic issue. Their growth is only just beginning, as they
are among the major providers of pharmaceutical innovation.
There are about ten bio-drugs currently on the market for rheumatoid arthritis with an
average annual treatment cost of 8 to 12 000 euros per patient. This cost is 20 times higher
than that of sDMARDs. However, among patients treated with biotherapy, clinical practice
shows that approximately one-third (33%) will not respond to the selected bio-drugs.
In the event of non-response, physicians currently have no choice but to rotate empirically
between different treatments, as no tools capable of predicting response or non-response to
these molecules are currently available. SinnoTest® software, a predictive algorithm for
responding to bDMARDs by analyzing proteomic biomarkers, will clarify this choice of
prescription for patients with failed RA of a first bDMARD in the anti-TNF family.